牛津醇 尼塔佐胺组合在实验性神经囊病 - 抗炎和囊效应
Jefferson Aber Alves Araújo1, Taynara Cristina Gomes1, Vanessa Cindy Neres Lima1
1Tropical Pathology and Public Health Institute, Federal University of Goias, Goiânia, Goiás, CEP: 74605-050, Brazil.
Experimental parasitology
|April 27, 2024
概括
奥克斯芬达和尼塔佐胺的组合显示出治疗神经囊硬化症 (NCC) 的前景,减少炎症和寄生虫的存在. 这种新的治疗方法可能会为这种寄生性脑部感染提供比目前治疗方法更安全的替代方案.
科学领域:
- 寄生虫学的寄生虫学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经囊病 (NCC) 是一种严重的寄生性脑部感染,由Taenia solium幼虫引起.
- 目前用于NCC的治疗方法,如阿尔本达和普拉齐昆,几十年来一直保持不变,并可能导致显著的副作用.
- 探索新的抗虫药物组合对于改善NCC管理和患者结果至关重要.
研究的目的:
- 调查联合牛芬达和尼塔佐化物治疗对实验性神经囊性瘤的组织病理影响.
- 评估这种药物组合在减少寄生虫负载和脑组织相关炎症方面的疗效.
- 为了比较组合治疗与单一治疗和对照组的安全性和有效性.
主要方法:
- 在Balb/c小鼠中使用T. crassiceps cysticerci.诱导实验性神经囊性.
- 小鼠被分为接受NaCl (对照组),单独接受oxfendazole (OXF) 或nitazoxanide (NTZ) 或OXF/NTZ组合治疗的组.
- 进行了宏观和显微分析,以评估寄生虫阶段和炎症反应 (周周血管炎,PMN,MN透).
主要成果:
- 与单一治疗相比,组合治疗导致末期囊的存在率更高.
- 与OXF或NTZ单一治疗诱导的周围炎水平高于对照组.
- 与单疗法和对照组相比,OXF/NTZ组合治疗显示炎症细胞透率 (PMN和MN) 显著降低.
结论:
- 奥克斯芬达和尼塔佐胺的组合对神经囊硬化症治疗有好处.
- 这种组合疗法有助于对寄生虫进行破坏,同时尽量减少大脑组织中有害的炎症损伤.
- 西米达衍生物,如牛达,与其他囊杀药相结合,为更安全,更有效的NCC管理提供了有希望的策略.
相关概念视频
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
160
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
198
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
198
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
272
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
272
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160


